Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

Recent Price Performance and Market Context

Akums Drugs has outperformed its sector and the Sensex benchmark in the short term. Over the past week, the stock appreciated by 4.90%, while the Sensex declined by 1.00%. Year-to-date, the stock has marginally declined by 1.99%, yet this is still better than the Sensex's 5.28% fall. The stock's intraday high on 01-Feb reached ₹454.95, a 3.35% increase from the previous close, signalling strong buying interest during the session.

Notably, the stock has been trading above its 5-day, 20-day, and 50-day moving averages, indicating positive short- to medium-term momentum. However, it remains below its 100-day and 200-day moving averages, suggesting that longer-term trends have yet to fully turn bullish. Liquidity remains adequate for trading, with the stock supporting trade sizes of approximately ₹0.08 crore based on recent volumes.

Valuation and Profitability Insights

One of the key factors supporting the recent rise in Akums Drugs’ share price is its attractive valuation. The company trades at a price-to-book value of 2.2, which investors may find reasonable given its return on equity (ROE) of 9.7%. While this ROE is modest, it indicates some level of profitability relative to shareholder equity. More strikingly, the company’s profits have surged by 1362% over the past year, a remarkable increase that contrasts with the stock’s negative price return of nearly 20% during the same period.

This divergence between profit growth and share price performance suggests that the market may be gradually recognising the company’s improving earnings potential, which could be driving the recent upward price movement. However, it is important to note that despite this profit growth, the company’s long-term fundamentals remain mixed, with net sales growing at a modest annual rate of 6.10% and operating profit increasing by 17.54% over the last five years.

Institutional Investor Confidence

Another significant driver behind the stock’s recent rise is the increasing participation of institutional investors. Over the previous quarter, institutional holdings in Akums Drugs increased by 4%, bringing their total stake to 15.55%. Institutional investors typically possess greater analytical resources and a longer-term investment horizon, which can lend credibility to the stock’s prospects and encourage other investors to follow suit.

Despite this positive institutional interest, some caution is warranted. The company’s quarterly profit before tax (excluding other income) has declined by 49.6% compared to the previous four-quarter average, and quarterly profit after tax has fallen by 50.1%. Additionally, interest expenses have surged by 380.25% in the latest six-month period, which could weigh on future profitability.

Long-Term Challenges and Market Underperformance

Akums Drugs has underperformed the broader market over the last year, with a negative return of 19.95% compared to the BSE500’s positive 5.79%. This underperformance reflects concerns about the company’s weak long-term fundamentals. The average ROE of 9.7% is relatively low, and the company’s growth in net sales and operating profit, while positive, has been modest. These factors have likely contributed to investor caution and restrained the stock’s appreciation over the longer term.

Moreover, falling investor participation is evident from a 30.48% decline in delivery volume on 30 January compared to the five-day average, suggesting some hesitation among retail investors despite the recent price gains.

Conclusion: Why the Stock Is Rising Despite Challenges

In summary, Akums Drugs & Pharmaceuticals Ltd’s recent price rise on 01-Feb is primarily driven by short-term positive momentum, attractive valuation metrics, and growing institutional investor interest. The stock’s outperformance relative to its sector and the Sensex over the past week and its seven-day consecutive gains underscore renewed investor confidence.

However, this optimism is tempered by the company’s weak long-term fundamentals, including modest sales growth, declining quarterly profits, and rising interest expenses. The stock’s significant underperformance over the past year compared to the broader market also highlights ongoing challenges.

Investors should weigh the recent profit surge and institutional backing against these fundamental concerns when considering Akums Drugs for their portfolios. The current price appreciation may reflect a cautious reappraisal of the company’s prospects, but the mixed financial signals suggest that a careful, balanced approach remains prudent.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →